Pharmaceuticals, Biotechnology and Life Sciences
Probiodrug, a Germany-based biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease (AD) and other neurodegenerative disorders, has reported that Last Patient’s Last Visit (LPLV) occurred on 05 April 2017 in the currently running Phase 2a SAPHIR study investigating the QC-inhibitor PQ912 in patients with early AD.
e-Therapeutics, the drug discovery company, announced Thursday that Dr. Raymond Barlow has assumed his position as Chief Executive Officer.
PureTech Health’s subsidiary Akili announced results from a project EVO pilot study demonstrating improved cognitive control in children with sensory processing dysfunction and attentional deficits.
NHS England is now inviting for the 2017 Clinical Fellowship Scheme for practising pharmacists.
Allecra Therapeutics, a Germany-based clinical-stage biopharmaceutical company dedicated to the development of novel antibiotics to combat drug-resistant bacterial infections, has appointed Dr. Engelbert (Bert) Tjeenk Willink as a Chairman of the Board and Dr. Leon Hooftmanas as Chief Medical Officer.
Sanofi has appointed Bill Sibold, a current head of Sanofi Genzyme’s Global Multiple Sclerosis, Oncology and Immunology organization, as Executive Vice President Sanofi Genzyme and member of the Executive Committee, effective July 1, 2017.
Sosei Group Corporation’s subsidiary Heptares Therapeutics got milestone payment from AstraZeneca for working together on an immuno-oncology project.
Abzena, a life sciences group providing services and technologies to enable the development and manufacture of biopharmaceutical products, will initiate a placing to raise approximately £25 million to expand further its service offering, capacity and capabilities.
BD (Becton, Dickinson and Company), a medical technology company, has completed the acquisition of Israeli-based Caesarea Medical Electronics (CME), a global infusion pump systems manufacturer.
According to the report, the global market radiopharmaceuticals were valued at nearly $5.1 billion and $5.7 billion in 2014 and 2015, respectively.